Association of cyclophosphamide drug–metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors

H. Irene Su(Union Hospital), Angela DeMichele(University of Pennsylvania), Mary D. Sammel(University of Pennsylvania), Michelle Horn(University of Pennsylvania), Clarisa R. Gracia(University of Pennsylvania), Luke Velders(University of Pennsylvania), Jennifer M. Matro(University of Pennsylvania), Corrie A. Stankiewicz(University of Pennsylvania), Jamie Green(University of Pennsylvania)
Fertility and Sterility
April 20, 2009
10.1016/j.fertnstert.2009.03.034
Cited by 64

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
|Cell|2017|448
Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
|JNCI Journal of the National Cancer Institute|2006|344
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2021|255